v3.6.0.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2016
Jun. 30, 2016
Current assets:    
Cash $ 16,329 $ 23,014
Accounts receivable - trade 25 484
Accounts receivable - unbilled 75 122
Work in process 27 22
Prepaid expenses and other current assets 292 264
Total Current Assets 16,748 23,906
Fixed assets, net of accumulated depreciation 25,453 25,574
Intangible assets, net of accumulated amortization 1,960 2,092
Security deposit 27 28
Total Assets 44,188 51,600
Current liabilities:    
Accounts payable (related party of $158 and $200 as of December 31, 2016 and June 30, 2016, respectively) 731 1,177
Accrued expenses (related party of $635 and $623 as of December 31, 2016 and June 30, 2016, respectively) 905 920
Capital lease obligation - current portion 176 170
Deferred revenue 55 24
Total Current Liabilities 1,867 2,291
Capital lease obligation - net of current portion 25,175 25,265
Total Liabilities 27,042 27,556
Commitments and Contingencies
iBio, Inc. Stockholders’ Equity:    
Preferred stock - no par value; 1,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock - $0.001 par value; 175,000,000 shares authorized; 89,109,410 shares issued and outstanding as of December 31, 2016 and June 30, 2016 89 89
Additional paid-in capital 67,974 67,468
Accumulated other comprehensive loss (29) (29)
Accumulated deficit (63,881) (57,591)
Total iBio, Inc. Stockholders' Equity 4,153 9,937
Noncontrolling interest 12,993 14,107
Total Equity 17,146 24,044
Total Liabilities and Stockholders' Equity $ 44,188 $ 51,600

Source

v3.6.0.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Revenues $ 75 $ 134 $ 210 $ 294
Operating expenses:        
Research and development (related party of $206, $252, $445 and $478), net of grant income of $4, $0, $40 and $0) 1,049 704 1,869 1,255
General and administrative (related party of $187, $78, $362 and $78) 2,351 1,684 4,820 3,106
Total operating expenses 3,400 2,388 6,689 4,361
Operating loss (3,325) (2,254) (6,479) (4,067)
Other income (expense):        
Interest expense (related party of $483, $0, $966 and $0) (483) 0 (966) 0
Interest income 12 2 25 4
Royalty income 4 6 16 12
Total other income (expense) (467) 8 (925) 16
Consolidated net loss (3,792) (2,246) (7,404) (4,051)
Net loss attributable to noncontrolling interest 563 0 1,114 0
Net loss attributable to iBio, Inc. (3,229) (2,246) (6,290) (4,051)
Comprehensive loss:        
Consolidated net loss (3,792) (2,246) (7,404) (4,051)
Other comprehensive income (loss) - foreign currency translation adjustments 0 1 0 (8)
Comprehensive loss $ (3,792) $ (2,245) $ (7,404) $ (4,059)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.04) $ (0.03) $ (0.07) $ (0.05)
Weighted-average common shares outstanding - basic and diluted 89,109 77,326 89,109 77,316

Source

v3.6.0.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Cash flows from operating activities:    
Consolidated net loss $ (7,404) $ (4,051)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:    
Share-based compensation 506 643
Amortization of intangible assets 176 182
Depreciation 650 2
Loss on abandonment of intangible assets 0 17
Changes in operating assets and liabilities:    
Accounts receivable - trade 459 243
Accounts receivable - unbilled 47 (15)
Work in process (5) 0
Prepaid expenses and other current assets (28) (70)
Security deposit 1 0
Accounts payable (255) 190
Accrued expenses (15) 29
Deferred revenue 31 16
Net cash used in operating activities (5,837) (2,814)
Cash flows from investing activities:    
Additions to intangible assets (226) 0
Purchases of fixed assets (539) (5)
Net cash used in investing activities (765) (5)
Cash flows from financing activities:    
Payment of capital lease obligation (83) 0
Proceeds from exercise of warrants 0 63
Net cash (used in) provided by financing activities (83) 63
Effect of exchange rate changes 0 (6)
Net decrease in cash (6,685) (2,762)
Cash - beginning of period 23,014 9,494
Cash - end of period 16,329 6,732
Schedule of non-cash activities:    
Unpaid intangible assets included in accounts payable 197 40
Fixed assets included in accounts payable in FY 2016, paid in FY 2017 71 0
Unpaid fixed assets included in accounts payable 61 0
Supplemental cash flow information:    
Cash paid during the period for interest $ 966 $ 0

Source